MedTrace Logo

A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons

NCT00161434 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2008-01-10

No results posted yet for this study

Summary

The primary objective of this research study is to assess if daily valacyclovir therapy for suppression of HSV-2 reactivation is associated with a decrease in mucosal HIV shedding in individuals co-infected with both HSV-2 and HIV.

Conditions

  • Herpes Simplex
  • HIV Infections

Interventions

DRUG

valacyclovir

1 gram daily for 8 weeks

DRUG

placebo

matching placebo for 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Anna Wald, MD, MPH · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2006-06-30
Completion
2006-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00161434 on ClinicalTrials.gov